Valneva's Lyme vaccine data boosts shares by 7%
26/11/2025 08:13
** Shares of French biotech company Valneva VLS.PA rise around 7% after reporting strong efficiency and safety data for its Lyme disease vaccine candidate ** Kempen views the data as bolstering confidence in the vaccine's phase 3 development, calling the risk-reward profile "highly attractive" ** Broker says the results reveal a robust immune response and a favourable safety profile across all age groups six months after receiving a booster dose ** Study confirms vaccine benefits when administered annually before Lyme disease season (Reporting by Leo Marchandon) ((Leo.marchandon@thomsonreuters.com))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency